ASH 2018 | Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. He discusses the the results of the Phase Ib GO28440 study (NCT01671904) looking at the safety and efficacy of venetoclax in combination with bendamustine plus rituximab or obinutuzumab in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). He describes the high response rates, MRD outcomes and toxicity profile of this combination.
Get great new content delivered to your inboxSign up